Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE) (ACCELERATE)

This study has been completed.
Information provided by (Responsible Party):
The Medicines Company Identifier:
First received: April 22, 2008
Last updated: August 21, 2014
Last verified: August 2014
The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure >160 mmHg) in patients with intracerebral hemorrhage (i.e., bleeding in the brain; stroke).

Condition Intervention Phase
Drug: clevidipine
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE)

Resource links provided by NLM:

Further study details as provided by The Medicines Company:

Primary Outcome Measures:
  • Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine [ Time Frame: Within 30 minutes of study drug initiation ]
    The median time, in minutes, was estimated with its two-tailed 95% confidence interval from the time of the initiation of clevidipine infusion until the first observed SBP was achieved in the target range of ≤160 mmHg to ≥140 mmHg within the first 30 minutes of clevidipine treatment. If patients did not reach the blood pressure target range within the first 30 minutes, their data was considered censored at 30 minutes. If another IV and/or oral antihypertensive agent indicated for hypertension was administered less than 30 minutes prior to achieving the endpoint, the data was considered censored at the time when the additional or alternative antihypertensive agent was given.

Secondary Outcome Measures:
  • Percentage of Participants Achieving a SBP of ≤160 mmHg Within 30 Minutes of Initiation of Clevidipine [ Time Frame: Within 30 minutes of study drug initiation ]
    The percentage of patients who reached SBP of ≤160 mmHg within the first 30 minutes of initiation of clevidipine infusion was summarized. If an additional or alternative IV antihypertensive agent and/or oral antihypertensive agent was administered for hypertension prior to a patient achieving SBP≤160 mmHg during the initial 30-minute treatment period, then the patient was considered to have failed to reach this efficacy endpoint.

  • Percent Change From Baseline in Systolic Blood Pressure During the Initial 30 Minutes of Clevidipine Infusion [ Time Frame: Baseline through 30 minutes post initiation of clevidipine infusion ]
    Over the initial 30 minutes of the treatment period, the percent change from baseline (defined as immediately prior to study drug initiation) was summarized descriptively at 1, 2, 3, 4, 5, 6, 7, 10, 15, 20, 25, and 30 minutes after clevidipine initiation. Decreases in SBP from baseline were observed over the course of this time period.

  • Magnitude, Frequency and Duration of Systolic Blood Pressure Excursions (Calculated as Area Under the Curve [AUC]) Outside the Target Range Normalized Per Hour for the Duration of the Clevidipine Monotherapy Infusion [ Time Frame: Duration of the study drug infusion (up to 96 hours) ]
    Total AUC-SBP captures the magnitude and duration of SBP either above the upper limit of the target SBP range at 160 mm Hg or below the lower limit of 140 mm Hg and normalized per hour for the duration of clevidipine infusion. A larger value for AUC-SBP indicates greater SBP variability outside the target range.

  • Percent Time Blood Pressures Were Maintained Within the Target Range (Systolic Blood Pressure ≤160 mmHg to ≥140 mmHg) Over Each 24 Hour Period During Monotherapy Infusion of Clevidipine [ Time Frame: From study drug initiation through termination (up to 96 h) ]
    The percent time that SBP was maintained within the SBP target range (≤160 mmHg to ≥140 mmHg) was summarized for each 24-hour period of monotherapy of clevidipine infusion through 96 hours (0 -≤24 h, 24-≤48 h, 48-≤72 h, 72-≤96 h). For purposes of this analysis, SBP data were available from all mITT patients for the overall infusion period and from 0 to ≤24 hours of infusion; however, data was only available for 8 patients from 24 to ≤48 hours, 4 patients from 48 to ≤72 hours and 1 patient from 72 to ≤96 hours due to the variability in infusion durations >24 hours across patients.

  • Mean Dose of Clevidipine During the Treatment Period [ Time Frame: Up to 96 hours ]
    Mean total dose of clevidipine from study drug initiation to the end of clevidipine treatment

  • Median Dose of Clevidipine During the Treatment Period [ Time Frame: Up to 96 hours ]
    Mean total dose of clevidipine from study drug initiation to the end of clevidipine treatment

  • Proportion of Patients Requiring an Additional or Alternative Antihypertensive Agent(s) With or Without Clevidipine [ Time Frame: Up to 96 hours ]
    Additional or alternative antihypertensive agent(s) comprise the use of other antihypertensive agent(s) either with clevidipine (additional) or in place of clevidipine (alternative) for the indication of hypertension from the time of clevidipine initiation to clevidipine termination. For purposes of this analysis, additional or alternative antihypertensive agents did not include oral antihypertensives that were administered in order to transition IV clevidipine-treated patients to oral therapy during the transition period of the study.

  • Percent Change in Heart Rate During 30 of Initiation of Clevidipine [ Time Frame: From study drug initiation through each specified timepoint ]
    Multiple timepoints were assessed (minutes 1, 2, 3, 4, 5, 10, 15, 20, 30) for analysis of percent change in heart rate during the initial 30 minutes.

  • The Percentage of Patients Whose Systolic Blood Pressure is <90 mmHg Within 30 Minutes of the Initiation of Clevidipine Infusion [ Time Frame: Within 30 minutes of the initiation of study drug infusion ]

Enrollment: 37
Study Start Date: June 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: clevidipine
This will be a single-arm study with no reference therapy.
Drug: clevidipine

Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.

Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours.

Other Names:
  • clevidipine injectable emulsion
  • clevidipine emulsion
  • Cleviprex

Detailed Description:
This was a multicenter, single-arm, non-blinded dose titration efficacy and safety trial evaluating the ability of clevidipine, a vascular-selective L-type calcium channel antagonist, to rapidly control acute hypertension in patients with intracerebral hemorrhage. Informed consent was obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures. At screening, a clinical and neurological examination was carried out. For the purposes of this study, acute hypertension was defined as SBP >160 mmHg immediately prior to initiation of study drug. Approximately 30 to 40 patients with acute intracerebral hemorrhage (ICH) were planned to be enrolled with approximately 10 patients requiring monitoring of intracranial pressure (ICP). Infusion of study drug was initiated within 12 hours of ICH symptom onset. All eligible patients enrolled received clevidipine in an open label manner. Clevidipine was to be infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed, to obtain the target SBP range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. During the first 30 minutes, if the desired blood pressure lowering effect was not attained or maintained, an alternative intravenous (IV) antihypertensive agent(s), advised to be a different class other than calcium channel blockers, could be used with or without stopping the clevidipine infusion. The clevidipine infusion could continue for up to a maximum of 96 hours. Twenty-four hour follow-up computerized tomography (CT) scan results were recorded, including measurement of intracerebral hematoma volumes. Assessment of safety was performed throughout the treatment period and until 6 hours after termination of study drug. Patients were followed for 7 days following termination of the clevidipine infusion.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CT evidence of intracerebral hemorrhage (diagnosis and treatment within 12 hours of symptom onset)
  • Age 18 years or older
  • Baseline systolic blood pressure (immediately prior to initiation of clevidipine) >160 mmHg measured using an arterial line. ICP-monitored patients enrolled in the sub-study were enrolled if SBP at the time of enrollment was ≤160 mmHg
  • Required antihypertensive therapy to achieve systolic blood pressure ≤160 mmHg
  • Written informed consent obtained

Exclusion Criteria:

  • Decision for early surgical evacuation prior to 30 minutes of clevidipine
  • Receipt of an oral antihypertensive within 2 hours prior to initiation of clevidipine
  • Treatment with a continuous infusion of an IV antihypertension agent prior to initiation of clevidipine. Bolus treatment with urapidil (Germany only), labetalol or hydralazine was permitted. ICP-monitored patients enrolled in the sub-study could be enrolled with a continuous infusion of an IV antihypertensive agent prior to the initiation of clevidipine.
  • Intracerebral hematoma considered to be related to trauma by the neurologist or neurosurgeon
  • Aneurysmal sub-arachnoid hemorrhage
  • Glasgow coma score of <5 and fixed dilated pupils
  • Expectation that the patient would not tolerate or require intravenous antihypertensive therapy for a minimum of 30 minutes
  • Known or suspected aortic dissection
  • Acute myocardial infarction on presentation
  • Positive pregnancy test or known pregnancy
  • Intolerance or allergy to calcium channel blockers
  • Allergy to soybean oil or egg lecithin
  • Known liver failure, cirrhosis or pancreatitis
  • Prior directives against advanced life support
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00666328

United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010-2975
United States, Hawaii
The Queens Medical Center
Honolulu, Hawaii, United States, 96813
United States, Maryland
The John Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Maine Medical Center
Portland, Massachusetts, United States, 04102
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Guilford Neurologic - Moses H Cone Health System
Greensboro, North Carolina, United States, 27405
United States, Ohio
Cleveland Clinic Hospitals
Cleveland, Ohio, United States, 44195
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Thomas Jefferson University Stroke Research
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
The University Health Science Center at S.A.
San Antonio, Texas, United States, 78229-3900
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84157
Universitätsklinikum Leipzig
Liebigstraße 22a, Leipzig, Germany, D-04103
Universitatsklinikum Erlangen
Erlangen, Germany, D91054
Universitatsklinikum Heidelberg
Heidelberg, Germany, D69120
Sponsors and Collaborators
The Medicines Company
Principal Investigator: Carmelo Graffagnino, MD Duke University
  More Information

Responsible Party: The Medicines Company Identifier: NCT00666328     History of Changes
Other Study ID Numbers: TMC-CLV-07-02
Study First Received: April 22, 2008
Results First Received: July 25, 2012
Last Updated: August 21, 2014

Keywords provided by The Medicines Company:
Intracranial Pressure
Antihypertensive Agent
Calcium Channel Blocker

Additional relevant MeSH terms:
Cerebral Hemorrhage
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017